Amphastar Pharmaceuticals (NASDAQ:AMPH) Sets New 12-Month Low - Should You Sell?

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $24.94 and last traded at $25.06, with a volume of 47436 shares trading hands. The stock had previously closed at $26.61.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Friday, March 21st. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday.

Amphastar Pharmaceuticals Trading Up 2.7 %

The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The stock has a market cap of $1.15 billion, a P/E ratio of 8.05, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. The stock's 50-day moving average is $28.68 and its two-hundred day moving average is $38.14.

Insider Activity

In other news, CFO William J. Peters sold 4,231 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares of the company's stock, valued at $2,681,377.02. This represents a 4.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 27.10% of the company's stock.

Remove Ads

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC raised its position in shares of Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after buying an additional 493 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Amphastar Pharmaceuticals by 806.5% during the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after purchasing an additional 871 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Amphastar Pharmaceuticals during the fourth quarter valued at approximately $38,000. Tower Research Capital LLC TRC lifted its stake in shares of Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after purchasing an additional 348 shares during the last quarter. Finally, Huntington National Bank boosted its holdings in shares of Amphastar Pharmaceuticals by 36.9% in the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock worth $50,000 after purchasing an additional 361 shares during the period. Institutional investors own 65.09% of the company's stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.